GLP-1 Peptide FAQ: 15 Questions Patients Ask Most Before Starting Treatment

GLP-1 medications have crossed from clinical obscurity into mainstream conversation faster than almost any therapeutic class in recent memory. Yet for every person who has started treatment, several more are sitting with questions their primary care visit did not fully answer. What exactly is a GLP-1 peptide? Who is it appropriate for? What should you check before your first injection? What separates semaglutide from tirzepatide — and does that difference matter for you?

This guide answers the 15 questions that come up most consistently among people seriously considering GLP-1 treatment — drawing from clinical trial data, FDA prescribing guidance, and current endocrinology practice standards. The goal is not to replace a conversation with your prescriber; it is to ensure that conversation is a productive one.

PART 1 OF 4  What Is GLP-1? — The Foundational Layer

Q1. Is GLP-1 actually a peptide, and what does that mean?

Yes — GLP-1 (glucagon-like peptide-1) is a naturally occurring peptide hormone. In biochemical terms, a peptide is a short chain of amino acids, smaller than a full protein but capable of highly specific biological signaling. GLP-1 is a 30-amino acid incretin — a gut-derived hormone released by L-cells in the distal small intestine and colon in response to nutrient ingestion.

Its classification as a peptide matters because peptides act as molecular messengers. GLP-1 does not store energy or build tissue the way macronutrients do — it signals. Specifically, it signals the pancreas, brain, and GI tract to coordinate a metabolic response to a meal. For a broader grounding in how peptides function as biological communicators, Meto's clinical guide, How Peptides Work in the Body, is a useful primer before diving into GLP-1 medications specifically.

Q2. How does GLP-1 work in the body?

GLP-1 operates through four primary physiological mechanisms — each relevant to why it has become central to metabolic medicine:

• Glucose-dependent insulin secretion. GLP-1 binds to receptors on pancreatic beta cells, stimulating insulin release only when blood glucose is elevated. This glucose-dependency is clinically significant: it substantially reduces the hypoglycemia risk associated with sulfonylureas or exogenous insulin.
• Glucagon suppression. GLP-1 inhibits alpha-cell secretion of glucagon — the counter-regulatory hormone that raises blood sugar. Suppressing glucagon lowers hepatic glucose output, improving post-meal glycemic control.
• Gastric emptying delay. GLP-1 slows the rate at which the stomach empties into the small intestine. This blunts the post-meal glucose spike and, critically, prolongs satiety after eating.
• Central appetite regulation. GLP-1 receptors are expressed throughout the hypothalamus and brainstem. Activation of these receptors reduces appetite and food-reward signaling, which explains why GLP-1 medications reduce caloric intake well beyond what gastric slowing alone would produce.

Q3. What's the difference between natural GLP-1 and GLP-1 receptor agonist medications?

Your body already produces GLP-1 — every meal triggers its release. The problem is half-life. Endogenous GLP-1 is degraded rapidly by the enzyme dipeptidyl peptidase-4 (DPP-4), with a circulating half-life of approximately 1–2 minutes. This makes natural GLP-1 pharmacologically useless as a standalone therapeutic.

GLP-1 receptor agonists (GLP-1 RAs) are synthetic analogs engineered to resist DPP-4 degradation. By modifying the peptide's molecular structure — through amino acid substitution or fatty acid conjugation — pharmaceutical chemists extended the half-life from minutes to hours or weeks, depending on the formulation. This is why they are classified as receptor agonists, not replacement hormones: they activate the same receptors as endogenous GLP-1, but with sustained, pharmacologically meaningful duration.

Q4. What conditions are GLP-1 medications officially approved to treat?

GLP-1 receptor agonists carry FDA approvals across several indications, depending on the specific drug:

• Type 2 diabetes mellitus — the original and primary indication for all GLP-1 RAs.
• Chronic weight management — Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) are FDA-approved for obesity (BMI ≥30) or overweight with at least one weight-related comorbidity (BMI ≥27).
• Cardiovascular risk reduction — Ozempic (semaglutide 1mg) carries FDA approval for reducing major cardiovascular events in adults with T2D and established cardiovascular disease, based on the SUSTAIN-6 trial.
• Chronic kidney disease with T2D — semaglutide received expanded FDA approval in 2024 for CKD risk reduction, based on the FLOW trial outcomes.

Off-label use for metabolic-associated steatotic liver disease (MASLD), PCOS-related metabolic dysfunction, and perimenopause-related weight gain is supported by growing evidence, though not yet reflected in formal labeling for all agents.

PART 2 OF 4  The Drugs — Semaglutide, Tirzepatide & the Landscape

Q5. What are the most common GLP-1 medications available today?

Semaglutide and tirzepatide now dominate clinical prescribing for metabolic management due to superior efficacy data. See Meto's clinical overview of GLP-1 medications for a current breakdown of each agent, including dosing protocols and formulation details.

Q6. What is semaglutide, and how is it different from other GLP-1 drugs?

Semaglutide is a once-weekly GLP-1 receptor agonist developed by Novo Nordisk. Its clinical profile distinguishes it from earlier GLP-1 agents on three dimensions:

• Duration. Its molecular structure — featuring fatty acid side chains that bind to albumin — gives it a half-life of approximately 7 days, enabling once-weekly dosing versus the daily injections required by liraglutide.
• Efficacy. The STEP 1 trial (Wilding et al., NEJM, 2021) demonstrated a mean body weight reduction of 14.9% over 68 weeks with semaglutide 2.4mg in adults with obesity — an outcome historically associated only with bariatric surgery.
• Formulation breadth. It is the only GLP-1 RA available in an oral formulation (Rybelsus), though oral bioavailability requires strict administration protocols and achieves lower plasma concentrations than the injectable forms.

Q7. Semaglutide vs. tirzepatide — which is more effective?

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. This dual agonism produces additive or synergistic metabolic effects that are mechanistically distinct from GLP-1 activation alone.

In the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022), participants receiving tirzepatide 15mg achieved a mean weight reduction of 20.9% over 72 weeks — meaningfully greater than semaglutide's STEP 1 outcomes. A 2023 real-world retrospective analysis published in JAMA Internal Medicine similarly favored tirzepatide on weight endpoints.

"More effective on average" does not mean better for every patient. Individual response varies based on GIP receptor sensitivity, baseline metabolic phenotype, GI tolerance, insurance coverage, and cost. The right drug is the one that works within your specific biological and practical context — a determination best made with a clinician, not from aggregate trial data alone.

Q8. Are compounded GLP-1 peptides the same as brand-name drugs?

Not reliably. Compounded semaglutide became widespread during the 2023–2024 supply shortage, when FDA-designated drug shortages permitted compounding pharmacies to legally produce versions of the molecule. As of early 2025, the FDA removed semaglutide from the shortage list and has since taken enforcement action against compounders producing it without a valid shortage basis.

Compounded versions are not FDA-approved and are not required to demonstrate the same purity, potency, or sterility standards as brand-name drugs. Some compounders use semaglutide sodium or acetate salt formulations — not the free base used in Ozempic and Wegovy — and these variants have not been studied in clinical trials. Meto's clinical review of research peptides vs. pharmaceutical-grade options covers the safety and quality considerations in full.

PART 3 OF 4  Before You Start — Eligibility, Safety & Real Expectations

Q9. Who is a good candidate for GLP-1 treatment?

General clinical eligibility criteria for GLP-1 treatment in chronic weight management:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, T2D, dyslipidemia, obstructive sleep apnea)
• Adults with T2D inadequately controlled on lifestyle modification and/or first-line agents such as metformin

The ADA 2024 Standards of Medical Care in Diabetes now recommend GLP-1 RAs as preferred second-line agents in T2D patients with established cardiovascular disease, CKD, or high cardiovascular risk — regardless of HbA1c level. Eligibility criteria otherwise vary by drug, indication, country, and insurer.

Meto's Prescription Weight Loss Program includes a structured eligibility assessment as part of the clinical intake process, matched to a provider experienced in metabolic medicine.

Q10. What are the most common side effects of GLP-1 medications?

GI effects are by far the most frequently reported, and they are dose-dependent and typically transient:

• Nausea — the most common side effect, particularly during the titration phase. In most patients, it resolves within 4–8 weeks as the body adapts to the drug.
• Vomiting, diarrhea, constipation — each occurs in 10–30% of patients in major clinical trials, with individual variation in which GI symptom predominates.
• Eructation and dyspepsia — common with gastric slowing; typically mild and manageable through dietary adjustments.

Beyond the GI profile, several other effects warrant clinical attention:

• Muscle mass reduction — a real concern with rapid weight loss on GLP-1 therapy. Research suggests that 25–40% of weight lost may come from lean tissue rather than adipose. Resistance exercise (minimum three sessions per week) and adequate protein intake (1.2–1.6g/kg body weight) are the primary clinical tools to mitigate this.
• Fatigue — reported during the titration phase; typically resolves as the dose stabilizes.
• Pancreatitis — rare but serious. Patients with a personal history of pancreatitis should discuss risk carefully with their prescriber before initiating any GLP-1 RA.
• Gallbladder events — increased incidence of cholelithiasis has been observed with rapid weight loss. Pre-existing gallbladder disease warrants clinical discussion.
• Thyroid C-cell signal — rodent studies showed thyroid C-cell hyperplasia with GLP-1 RAs. No confirmed causal signal has emerged in human trials or post-marketing surveillance, but this observation informs the contraindications listed in all GLP-1 RA prescribing labels.

Q11. Are there people who should NOT take GLP-1 medications?

Absolute and relative contraindications include:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Personal or family history of Multiple Endocrine Neoplasia type 2 (MEN2)
• Active or recent pancreatitis
• Pregnancy and breastfeeding — GLP-1 RAs should be discontinued at least 2 months before planned conception
• Severe gastroparesis or other significant GI motility disorders
• Documented hypersensitivity to any component of the formulation

Concurrent use with sulfonylureas or basal insulin requires dose adjustments to reduce hypoglycemia risk. Patients with moderate-to-severe chronic kidney disease should also discuss renal dosing considerations with their prescriber.

Q12. What lab tests or health markers should I check before starting?

This is one of the most underasked questions among pre-treatment patients — and one of the most clinically important. A responsible pre-treatment workup provides both a contraindication screen and a baseline from which to measure response:

• HbA1c and fasting glucose — establish baseline glycemic status; essential for T2D diagnosis and therapeutic target-setting
• Fasting insulin and HOMA-IR — contextualize the degree of insulin resistance, which influences expected drug response
• Lipid panel — baseline cardiovascular risk assessment; GLP-1 therapy often improves lipid profiles, and tracking changes is clinically meaningful
• TSH — thyroid-stimulating hormone to rule out undiagnosed hypothyroidism, which can confound metabolic response to treatment
• eGFR and serum creatinine — renal function assessment; dose adjustments or contraindication in moderate-to-severe CKD
• ALT, AST, and GGT — baseline liver function; particularly relevant in metabolic-associated fatty liver disease (MASLD), which frequently co-exists with obesity and insulin resistance
• Weight, BMI, and waist circumference — documented baseline for tracking clinical response and body composition changes over time

Meto's Comprehensive Metabolic Panel covers the core markers in this workup and includes a clinician-reviewed report with next-step recommendations — a practical starting point for patients who haven't had recent metabolic bloodwork.

PART 4 OF 4  Starting Treatment — Timeline, Lifestyle & Costs

Q13. How long does it take to see results on a GLP-1 medication?

The honest answer: it depends on what you are measuring and where you started.

• Glycemic improvements in patients with T2D can appear within 2–4 weeks of initiation, as improved insulin secretion and glucagon suppression begin reducing post-meal glucose excursions.
• Weight loss follows a slower, dose-dependent curve. In the STEP 1 trial, the mean weight reduction was approximately 6% at 12 weeks, 11% at 28 weeks, and 14.9% at 68 weeks with semaglutide 2.4mg. The titration schedule — starting at 0.25mg and escalating over 16–20 weeks — intentionally slows dose escalation to improve GI tolerability, meaning most patients do not reach their full therapeutic dose until 3–4 months into treatment.
• Cardiovascular biomarkers — blood pressure, LDL-C, inflammatory markers — often begin improving in parallel with early weight loss, typically within 12–16 weeks of sustained treatment.

Patience is not optional with GLP-1 therapy. Results seen at 16 weeks are not the ceiling — they are frequently the beginning of a sustained trajectory. The STEP 4 trial (Rubino et al., JAMA, 2021) demonstrated that discontinuing semaglutide after an initial weight-loss phase leads to substantial weight regain, underscoring that GLP-1 treatment is most effective as a long-arc, ongoing intervention rather than a short-course fix.

Q14. Do I need to change my diet and exercise while on a GLP-1 medication?

Every major GLP-1 clinical trial was conducted alongside a structured behavioral intervention — dietary counseling, increased physical activity, and lifestyle modification protocols. GLP-1 medications reduce appetite and improve metabolic signaling, but they do not override the fundamental physiology of energy balance.

Two specific concerns merit direct clinical attention:

• Muscle mass loss. Rapid weight loss at the rates seen with GLP-1 therapy includes lean mass reduction. Resistance training at a minimum of three sessions per week, combined with protein intake at the higher end of the recommended range (1.2–1.6g/kg body weight), are the main clinical tools to preserve muscle during treatment. This is not optional for patients with concerns about long-term metabolic rate and functional capacity.
• Dietary composition during titration. High-fat meals tend to exacerbate nausea and GI discomfort in the early weeks of treatment. Smaller, more frequent meals and moderating dietary fat content during the titration phase significantly improves tolerability and patient adherence.

Q15. How much do GLP-1 medications cost, and are they covered by insurance?

US list prices, before savings programs or insurance coverage:

• Ozempic (semaglutide 0.5–2mg): approximately $900–$1,000/month
• Wegovy (semaglutide 2.4mg): approximately $1,300–$1,400/month
• Mounjaro/Zepbound (tirzepatide): approximately $1,000–$1,200/month

Insurance coverage is the central access variable. Coverage for T2D-indicated GLP-1 drugs (Ozempic, Mounjaro) is more consistent across major commercial insurers than coverage for obesity-indicated formulations (Wegovy, Zepbound), which many plans still exclude. This gap is slowly narrowing as cardiovascular and renal outcomes data strengthen the case for broader coverage.

Manufacturer savings programs for commercially insured, eligible patients:

• NovoCare (Novo Nordisk) — can reduce out-of-pocket costs to as low as $25/month for semaglutide products
• Lilly Savings Card (Eli Lilly) — offers comparable savings for Mounjaro and Zepbound

For patients without insurance or with excluded coverage, Meto's self-pay options offer transparent, affordable pricing. Average session cost with insurance through Meto: $25. For details, visit Meto's how it works page.

The Meto Perspective

GLP-1 medications are among the most clinically significant therapeutic developments in metabolic medicine in decades. But their value is not in the molecule alone — it is in the clinical context surrounding it.

At Meto, we see the patient population behind these 15 questions every day: people who are metabolically complex, often carrying co-existing insulin resistance, thyroid dysfunction, PCOS, or fatty liver disease, and who need more than a prescription and a three-month follow-up. GLP-1 therapy, when appropriate, is one tool within a broader metabolic care strategy — not a standalone fix.

What matters clinically is matching the right patient to the right drug at the right dose, with a pre-treatment workup that catches contraindications early, ongoing lab monitoring to track response, and lifestyle integration that protects lean mass and long-term metabolic health. That is the standard of care Meto providers practice.

Ready to find out if a GLP-1 medication is right for you? Meto's metabolic specialists conduct thorough eligibility assessments — including lab review and clinical history — before any treatment decision is made.

Get matched with a GLP-1 specialist at Meto →